An Open Label Study on Amisulpride in Augmentation with Atypical Antipsychotics in Treatment Resistant Patients of Schizophrenia and Schizoaffective Disorders.
Artigo
em Inglês
| IMSEAR
| ID: sea-158022
ABSTRACT
The authors report an open label study in treatment resistant patients of schizophrenia and schizoaffective disorders. The patients who were earlier being treated with atypical antipsychotics were put on combination of amisulpride and atypical antipsychotics and efficacy as well as safety of the combination was assessed. Method:
A study of 6 weeks duration was conducted on 30 patients (9 women, 21 men).The mean dose of amisulpride used was from 250.00 mg/day + 91.65. SAPS, SANS, CGI-S scales were applied. 4 patients dropped out of study. 26 patients completed 6 weeks duration.Results:
There was significant improvement in negative symptoms, positive symptoms, cognition especially in old chronic schizophrenics.Only two patients developed extrapyramidal symptoms.Improvement in all symptoms was remarkable.Conclusion:
The combination of amisulpride with atypical antipsychotics is a promising option in patients who are resistant to treatment.
Texto completo:
DisponíveL
Índice:
IMSEAR (Sudeste Asiático)
Assunto principal:
Transtornos Psicóticos
/
Esquizofrenia
/
Sulpirida
/
Antipsicóticos
/
Feminino
/
Humanos
/
Masculino
/
Espectro da Esquizofrenia e Outros Transtornos Psicóticos
Idioma:
Inglês
Ano de publicação:
2008
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS